TP53 and acute myeloid leukemia: The importance of TP53 mutations specifically for our HRMS subgroup is also consistent with the guidelines of the National Comprehensive Cancer Network, which classify AML patients with normal cytogenetics into the poor/adverse risk category if they harbor TP53 mutations (Daver et al., 2020).